Technical Analysis for NTLA - Intellia Therapeutics, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Up | Up | Up |
| Historical NTLA trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| NR7 | Range Contraction | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Morning Star | Bullish | 0.36% | |
| Wide Bands | Range Expansion | 0.36% | |
| 20 DMA Support | Bullish | 6.00% | |
| Non-ADX 1,2,3,4 Bullish | Bullish Swing Setup | 6.00% | |
| Spinning Top | Other | 6.00% | |
| Wide Bands | Range Expansion | 6.00% | |
| Down 3 Days in a Row | Weakness | 6.00% | |
| Wide Bands | Range Expansion | 2.26% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time | |
|---|---|---|
| 10 DMA Support | 2 days ago | |
| Down 2 % | 2 days ago | |
| Down 1% | 2 days ago | |
| 10 DMA Resistance | 2 days ago | |
| Rose Above Previous Day's High | 2 days ago |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/07/2020
- Sector: Healthcare
- Industry: Biotechnology
Intellia Therapeutics Inc., a gene editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, hepatitis B virus, and inborn errors of metabolism; and ex vivo applications of the technology in chimeric antigen receptor T cell and hematopoietic stem cell product candidates. It has a strategic collaboration and license agreement with Novartis focused on the development of new ex vivo CRISPR/Cas9-based therapies. Intellia Therapeutics Inc. was formerly known as AZRN, Inc. and changed its name to Intellia Therapeutics Inc. in July 2014. The company was founded in 2014 and is headquartered in Cambridge, Massachusetts.
Medicine Biotechnology Biology Immune System Emerging Technologies Molecular Biology Genetics Antitrypsin Deficiency Inborn Errors Of Metabolism Genome Editing Liver Diseases Cas9 Chimeric Antigen Receptor CRISPR Transthyretin Amyloidosis
Medicine Biotechnology Biology Immune System Emerging Technologies Molecular Biology Genetics Antitrypsin Deficiency Inborn Errors Of Metabolism Genome Editing Liver Diseases Cas9 Chimeric Antigen Receptor CRISPR Transthyretin Amyloidosis
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 27.07 |
| 52 Week Low | 9.18 |
| Average Volume | 892,672 |
| 200-Day Moving Average | 17.76 |
| 50-Day Moving Average | 21.72 |
| 20-Day Moving Average | 23.16 |
| 10-Day Moving Average | 24.69 |
| Average True Range | 1.85 |
| ADX | 25.1 |
| +DI | 32.40 |
| -DI | 21.01 |
| Chandelier Exit (Long, 3 ATRs ) | 21.51 |
| Chandelier Exit (Short, 3 ATRs ) | 24.37 |
| Upper Bollinger Band | 27.52 |
| Lower Bollinger Band | 18.80 |
| Percent B (%b) | 0.7 |
| BandWidth | 37.68 |
| MACD Line | 1.01 |
| MACD Signal Line | 0.97 |
| MACD Histogram | 0.0433 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 26.64 | ||||
| Resistance 3 (R3) | 26.57 | 25.93 | 26.35 | ||
| Resistance 2 (R2) | 25.93 | 25.48 | 25.96 | 26.25 | |
| Resistance 1 (R1) | 25.41 | 25.21 | 25.09 | 25.48 | 26.16 |
| Pivot Point | 24.77 | 24.77 | 24.61 | 24.80 | 24.77 |
| Support 1 (S1) | 24.25 | 24.32 | 23.93 | 24.32 | 23.64 |
| Support 2 (S2) | 23.61 | 24.05 | 23.64 | 23.55 | |
| Support 3 (S3) | 23.09 | 23.61 | 23.45 | ||
| Support 4 (S4) | 23.16 |
